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PEMBANGUNAN BIOSENSOR TAHAN HABA MULTIPLEKS  
LAMP-ICT-DNA UNTUK PENGESANAN PANTAS  
Entamoeba histolytica DAN SPESIES-SPESIES Entamoeba BUKAN PATOGEN  
 
ABSTRAK 
Entamoeba histolytica adalah satu-satunya spesies Entamoeba yang berpotensi 
menyebabkan amebiasis invasif pada manusia. Ameba ini menjangkiti kira-kira 10% 
daripada populasi dunia dan menyebabkan 100,000 kematian setiap tahun di negara 
endemik. Asai diagnostik yang baharu diperlukan untuk membezakan E. histolytica 
daripada Entamoeba dispar dan Entamoeba moshkovskii, iaitu dua spesies Entamoeba 
yang bukan patogen tetapi mempunyai morfologi yang sama. Kaedah mikroskopi tidak 
dapat membezakan ketiga-tiga Entamoeba tersebut. Di samping itu, kaedah ini bukan 
sahaja memerlukan tenaga mahir, malah ia juga tidak sensitif. Kaedah pengesanan lain 
seperti asai biokimia, teknik pengesanan antibodi dan antigen mengambil masa yang 
lama dan/atau memerlukan rangkaian sejuk. Amplifikasi isoterma berpengantara 
gelung (LAMP) yang hanya memerlukan suhu amplifikasi tunggal berpotensi 
dijadikan asai point penjagaan. Maka kajian ini bertujuan untuk menformulasi 
campuran reagen-kering tripleks LAMP untuk mengesan E. histolytica, Entamoeba 
spp. dan kawalan amplifikasi dalaman serta membangunkan biosensor NALFIA tanpa 
penghibridan untuk mengesan amplifikon-amplikon LAMP tersebut. Dua set primer 
yang mensasarkan E. histolytica dan Entamoeba spp. telah masing-masing direka 
bentuk berdasarkan gen E. histolytica SREHP dan gen E. histolytica subunit besar 
RNA ribosom. Di samping itu, satu set primer telah direka bentuk dan digabungkan 
dengan LAMP multipleks untuk berfungsi sebagai kawalan amplifikasi dalaman yang 
dapat mengesahkan keputusan negatif yang benar. Asai LAMP tripleks telah direka 
 xviii 
 
bentuk untuk menghasilkan amplikon bebenang dua yang dilabel pada dua penghujung 
dengan pengeraman selama 60 min pada 63°C diikuti dengan suhu penamatan pada 
80°C selama 5 min. Amplikon yang dilabel pada dua penghujung ditangkap oleh 
NALFIA biosensor melalui interaksi pertalian spesifik antara protein dengan hapten 
pada lokasi pengesanan. Amplikon yang dilabel fluoresein menghasilkan penglabelan 
hibrid dengan fluoresein antibodi yang dikonjugasikan pada nanopartikel emas. 
Pengagregatan nanopartikel emas menghasilkan keputusan dalam bentuk garisan 
merah/merah jambu yang dapat dilihat dengan mata kasar dalam masa 15 min. 
Pembangunan asai LAMP tripleks bukan sahaja mengurangkan masa amplifikasi, 
malah dapat mengelakkan penggunaan peralatan yang mahal dan tidak memerlukan 
kakitangan yang terlatih untuk mengendalikannya. Selain itu, biosensor NALFIA 
dapat menganalisis amplicon LAMP tanpa penggunaan elektroforesis gel agarosa yang 
mengambil masa yang agak lama dan menggunakan bahan yang merbahaya. Asai 
LAMP-NALFIA yang telah dibangunkan dalam bentuk reagen kering bukan sahaja 
tidak memerlukan rangkaian sejuk, malah ujian diagnostik ini dapat digunakan di 
tempat rawatan dan lapangan. Had pengesanan asai LAMP-NALFIA ialah 10 trofozoit 
E. histolytica manakala spesifikasinya adalah 100% apabila diuji dengan 71 
mikroorganisma lain. Campuran LAMP tripleks yang berasaskan reagen kering dan 
biosensor NALFIA mempunyai jangka hayat sekurang-kurangnya 181 hari 
berdasarkan Ujian Kestabilan Haba pada 37°C. Penggabungan dua pelantar asai ini 
telah berjaya memudahkan pengesanan molekular untuk E. histolytica dan spesies-
spesies Entamoeba yang bukan patogen.  
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DEVELOPMENT OF A THERMOSTABILISED MULTIPLEX  
LAMP-ICT-DNA BIOSENSOR FOR RAPID DETECTION OF  
Entamoeba histolytica AND NONPATHOGENIC Entamoeba SPECIES 
 
ABSTRACT 
 
Entamoeba histolytica is the only pathogenic Entamoeba species that can cause 
severe invasive intestinal amoebiasis in humans. Approximately 10% of the world 
population is estimated to be infected, in which 100,000 deaths were reported annually 
in endemic countries. New diagnostic assays are needed to distinguish E. histolytica 
from its nonpathogenic morphologically identical Entamoeba species, Entamoeba 
dispar and Entamoeba moshkovskii, as routine microscopy method is labour-intensive, 
requires highly skilled microscopist, low in sensitivity and unable to distinguish E. 
histolytica from its nonpathogenic species. Other detection methods such as 
biochemical assays and antibody as well as antigen detection techniques are either 
time-consuming and/or cold-chain dependent. Loop-mediated isothermal 
amplification (LAMP) that features single temperature amplification has created an 
opportunity to develop point-of-care assays. Thus, the present study aimed to 
formulate a dry-reagent triplex LAMP mix for detection of E. histolytica, Entamoeba 
spp. and the incorporated internal amplification control as well as to develop a non-
hybridisation-based NALFIA biosensor for detection of the LAMP amplicons. Two 
sets of specific primers targeting E. histolytica and Entamoeba spp. were designed 
based on E. histolytica serine-rich protein (SREHP) gene and E. histolytica large 
subunit ribosomal RNA gene, respectively. In addition, a set of primers was designed 
and incorporated into multiplex LAMP to serve as an internal amplification control to 
rule out false negative result. The triplex LAMP assay was designed to produce 
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double-labelled double-stranded amplicons with 60 min of incubation at 63°C 
followed by termination at 80°C for 5 min. These double-labelled amplicons were 
captured by NALFIA biosensor through specific affinity interaction between capture 
proteins with haptens on the reaction pad. The fluorescein labelled on each of the 
amplicons then immobilised fluorescein antibody conjugated gold nanoparticles, and 
aggregation of gold nanoparticles formed red/pinkish lines which were visualised with 
naked eye within 15 min. Development of triplex LAMP assay not only reduced the 
amplification time, it also eliminated the necessity of having thermal cycler which was 
costly and required trained personnel to operate. Besides, having NALFIA biosensor 
as amplicons analyser obviated the need for agarose gel electrophoresis which was 
time-consuming and utilised hazardous chemicals. The triplex LAMP-NALFIA assay 
that was developed in dry-reagent form was a cold-chain-free and ready-to-use 
diagnostic test. The detection limit of the assay was 10 E. histolytica trophozoites 
whereas the specificity was 100% when tested with 71 non-Entamoeba 
microorganism. The dry-reagent triplex LAMP mix and NALFIA biosensor had an 
estimated shelf-life of at least 181 days based on heat stability test conducted at 37°C. 
Development of the dry-reagent triplex LAMP mix coupled with a NALFIA biosensor 
had effectively simplified the molecular detection of E. histolytica and the 
nonpathogenic Entamoeba species. 
 
 
 1 
 
CHAPTER 1 
INTRODUCTION 
 
1.1 Amoebiasis 
Amoebiasis is an enteric disease caused by Entamoeba histolytica (Stanley, 
2003). This parasitic disease affects approximately 40 to 50 million individuals of 
world population and causes up to 100,000 deaths annually. It is the third leading cause 
of death among the parasitic infections after malaria and schistosomiasis (Walsh, 1986; 
Solaymani-Mohammadi and Petri, 2008; Hegazi et al., 2013). Approximately 10% of 
the infections are symptomatic ranging from dysentery to amoebic liver abscess (ALA) 
(Haque et al., 2003).  
Amoebiasis is divided into two categories based on its manifestation, namely 
invasive and non-invasive infections. Most non-invasive category was mostly reported 
as amoebic dysentery while invasive amoebiasis was mostly associated with ALA. An 
estimated 10% of intestinal amoebiasis became invasive when amoebae enter into 
bloodstream and traverse to other organs such as liver where infection could eventually 
lead to ALA. Among the clinical manifestations of extraintestinal amoebiasis, ALA is 
the most commonly reported and it could be fatal if treatment is delayed (Zlobl, 2001). 
Early diagnosis of ALA is challenging as liver abscesses can occur even without 
patient experiencing prior amoebic diarrhoea. Amoebiasis are commonly reported at 
low socio-economic and poor sanitation areas. High prevalence rates were found 
mostly in tropical countries of Central and South America, as well as India (Widmer 
and Nettleman, 1991). Besides people who live in endemic areas, other high risk 
groups include travelers and men who practiced oral-anal sex (Hung, 2007; Rivero et 
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al., 2008). Recent study conducted by Wong et al. (2016) showed the amoebiasis 
prevalence was 71% among the Orang Asli adults in peninsular Malaysia. 
Several drugs are available for effective treatment of intestinal and 
extraintestinal amoebiasis in which metronidazole and paromomycin are the most 
common prescription. However, due to their potential adverse side effects, these drugs 
should only be given to patients who are confirmed with amoebiasis (WHO, 1997). 
Physical conditions of patient including pregnancy should also be taken into 
consideration before prescribing the drug. The common side effects of metronidazole 
include vomiting, headache, nausea and abdominal discomfort (Upcroft and Upcroft, 
2001; Zlobl, 2001; Salles et al., 2003). A summary of commonly prescribed 
medication for amoebiasis positive patient with its side effect is showed in Table 1.1. 
 
1.2 Pathogenic Entamoeba species 
E. histolytica is a microaerophilic parasitic protozoan. To date, E. histolytica is 
the only Entamoeba species that is responsible for invasive amoebiasis. E. histolytica 
was first described from a case of patient with chronic dysentery in 1875 by Fedor 
Lösch in St. Petersburg, Russia. Later in 1893, Quincke and Roos described its cyst 
form followed by Fritz Schaudinn who named the species as E. histolytica in 1903 
(Maberti, 1994; Momen, 1994; Marshall et al., 1997). Although E. histolytica is not 
the only causative agent for amoebic dysentery, it is described to be the only 
opportunistic species that potentially cause a wide range of invasive diseases with 
massive host tissue destruction (Ralston and Petri, 2011). Those diseases include 
respiratory tract infections, ALA, cerebral and genitourinary amebiasis (Fotedar et al., 
2007a). Among them, ALA is the most commonly reported. ALA is associated with a  
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Table 1.1 Mechanism and adverse effect of treatment drug for amoebiasis 
Drug Mechanism Adverse Effect Comments 
Metronidazole  
Or Tinidazole 
Activated in anaerobic 
organisms by 
reduction of the 5-
nitro group. Activated 
compound damages 
DNA  
Metallic taste, nausea, 
vomiting, diarrhoea. 
(Rarely result in 
sensory neuropathies, 
central nervous 
system toxicity with 
ataxia, vertigo, 
seizures and 
encephalopathy.) 
 
Drug of choice for 
amoebic colitis and 
ALA. 
Paromomycin Aminoglycoside 
(inhibit protein 
synthesis) 
Nausea, vomiting, 
cramps, diarrhoea 
Drug of choice for 
intestinal amoebiasis. 
It should be 
administrated to all 
individuals following 
completion of 
metronidazole 
therapy.  
 
Iodoquinol  
 
unknown Headache, nausea, 
vomiting. Optic nerve 
damage and peripheral 
neuropathy reported in 
patient exceeding 
recommended dosage 
 
Alternative to 
paromomycin 
Diloxanide 
Furoate 
unknown Flatulence Alternative to 
paromomycin 
 
Adopted from (Stanley, 2003)  
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massive fluid-filled cavity in the parasite infected liver which can be fatal if left 
untreated (Maltz and Knauer, 1991). 
E. histolytica is a unicellular eukaryotic parasite that contain a nucleus and 
multiply through binary fission. It infects human host through ingestion of its cysts. 
Excystation takes place in host small intestine which produces 8 trophozoites per cyst, 
which then colonise the lumen and/or attach to mucus and epithelial cells of large 
intestine (Petri et al., 2002). It is a heterotrophy endoparasite that stays inside a host 
and require nutrient supplies from the colonised environment. The pleomorphic 
characteristic of trophozoite allows it to perform pseudopodia movement and travel to 
other part of human organ. Human is its primary host where it survives by consuming 
bacteria, red blood cells or food particles. E. histolytica was estimated to contain 14 
chromosomes with genome size of 24 mega-basepairs based on electrophoretic 
karyotyping via pulse gel electrophoresis (Baron, 1996; Stanley, 2003; Loftus et al., 
2005). 
The life cycle of E. histolytica involves two stages, namely infective cyst stage 
and motile trophozoite stage as shown in Figure 1.1 and Figure 1.2. Despite human 
being the primary host, other animals can be E. histolytica transient or accidental hosts. 
A quadrinucleate cyst which is activated by the intestinal secretions later developed 
into four motile metacystic trophozoites. The trophozoites develop and divide through 
binary fissions and produce 8 trophozoites in the intestine. When the colonised 
environment is not favorable, encystment takes place to produce a quadrinucleate 
infective cyst through two division processes, which then passes out along with host  
stool (Hankenson et al., 2003; Stanley, 2003; Rivera et al., 2010). 
E. histolytica cyst can survive and resist environment stress such as presence 
of gastric acid and oxygen. A cyst typically measures 10 to 20 µm in diameter, consists  
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Figure 1.1 Life cycle of E. histolytica  
Adopted from (CDC, 2010)  
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Figure 1.2 Structure of E. histolytica trophozoite and cyst  
Adopted from (CDC, 2010)  
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of four nuclei with cigar-shaped or rounded chromatoidal bars made of assemblies of 
glycogen. However, a vacuole and fewer nuclei may present in immature cyst. 
Presence of a central karyosome surrounded by peripheral chromatin dots in each 
nucleus is an important characteristic feature. Similarly, E. histolytica trophozoite also 
possesses such feature (Lohia, 2003). However, it is slightly bigger and measures 10 
to 60 µm in diameter and pleomorphic in shape. The trophozoite cytoplasm commonly 
contains fine ingested red blood cell and/or debris from bacteria. Since, E. histolytica 
is basically anaerobic, it acquires energy through anaerobic conversion of glucose and 
pyruvate to ethanol. 
Generally, E. histolytica is transmitted by fecal-oral route due to improper 
hygiene such as ingestion of cysts via dirty hands or objects (Hankenson et al., 2003). 
It could also be transmitted through sexual activities that involved oral-anal or oral-
genital contact. This may be the reason why more ALA incidents are reported to be 
higher in males than females with a ratio of 10:1 or higher (Akgun et al., 1999; Lee et 
al., 2009). Infective cyst is more resistant to environmental pressure, it can survive in 
stool for up to two weeks whereas only 10% of trophozoites were reported to be viable 
after 6 h in stool (Tan et al., 2010). The human host invasion of trophozoites often start 
from the intestinal compartment, then enter the portal vein, and spread 
haematogenously to the liver, lung, brain or skin. 
The pathogenesis of amoebiasis relies on the host-parasite interaction and 
virulence of trophozoites. Amoebiasis can be categorised into three different groups, 
which are asymptomatic infection, intestinal amoebiasis, and extraintestinal 
amoebiasis as shown in Table 1.2. Asymptomatic or mildly symptomatic is the most 
common manifestation which comprises 90% of the total reported cases based on 
microscopic examination (Walsh, 1986). Patients with asymptomatic colonisation of  
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Table 1.2 Classification of amoebiasis  
WHO Clinical Classification of 
Amoebiasis 
Pathophysiologic Mechanism 
Asymptomatic infection 
 
Symptomatic infection 
  
 Intestinal amoebiasis 
 A. Amoebic dysentery 
 B. Nondysenteric gastroenteritis 
 C. Amoeboma 
 D. Complicated intestinal 
 amoebiasis 
 E. Post-amoebic colitis 
  
 Extraintestinal amoebiasis 
 A. Non-specific hepatomegaly 
 
 B. Acute non-specific infection 
 C. Amoebic abscess 
 D. Amoebic abscess   
 complicated 
 E. Amoebic cutis 
 F. Visceral amoebiasis 
Colonization without tissue invasion 
 
Invasive infection 
 
 
Fulminant ulcerative intestinal disease 
Ulcerative intestinal disease 
Proliferative intestinal disease 
Perforation, haemorrhage, fistula 
 
Mechanism unknown 
 
 
Intestinal infection with no 
demonstrable invasion 
Amoebas in liver but without abscess 
Focal structural lesion 
Direct extension to pleura, lung, 
peritoneum, or pericardium 
Direct extension to skin 
Metastatic infection of lung, spleen, or 
brain 
Adopted from (Sodeman, 1996)  
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E. histolytica possibly clear their infection without showing any symptom of the 
disease. Colonised trophozoites may just reside in the infected individual as 
commensal. However, the opportunistic E. histolytica may cause amoebic dysentery 
or even invasive diseases if left untreated (Gathiram and Jackson, 1987; Haque et al., 
2001; Blessmann et al., 2002; Blessmann et al., 2006). Treatment is recommended for 
asymptomatic cyst carriers because statistics reveals up to 10% of individuals with 
asymptomatic E. histolytica colonisation developed into amoebic colitis or 
extraintestinal disease (Gathiram and Jackson, 1987; Haque et al., 2001).  
The clinical manifestation of amoebic colitis depends on the depth of the 
invasion which may vary from local mucosal erosion to mucosal ulceration. In 
intestinal amoebiasis cases, some patients showed intermittent diarrhoea which 
alternates with constipation. Fever is uncommon for E. histolytica infection, in which 
less than 40% were reported among amoebic patients (Adams and MacLeod, 1977). 
At the benign phase of intestinal amoebiasis, an individual may experience only mild 
to severe diarrhoea. Diarrhoea may be replaced by dysenteric stools when the lesion 
of mucosal increases. Occasionally, local invasion of trophozoites could induce a 
proliferative granulomatous response at the ulcerative site and turn it into a pseudo-
tumour which also known as amoeboma (Sodeman, 1996). 
 
1.3 Nonpathogenic Entamoeba species 
The nonpathogenic Entamoeba species that were found in human body 
included E. dispar, E. moshkovskii, Entamoeba coli, Entamoeba gingivalis, 
Entamoeba polecki, Entamoeba hartmanni and Entamoeba chattoni (Zlobl, 2001). 
Table 1.3 and Figure 1.3 show the summarised descriptions of these common amoebas.  
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Table 1.3 Morphologic features and pathogenicity of intestinal amoeba  
Characteristics E. histolytica, E. dispar and E. 
moshkovskii 
E. hartmanni E. coli E. polecki E. nana 
Trophozoites (size, 
nucleus, and 
movement) 
15 to 20 μm; one nucleus; actively 
motile cytoplasmic protrusions, 
quickly finger shaped pseudopodium 
8 to 10 μm; one nucleus; 
nonsuccessive 
20 to 25 μm; one 
nucleus; slow 
movement, short and 
blunt pseudopodium 
15 to 20 μm; one nucleus; 
motility resembles E. coli 
7 to 9 μm; one 
nucleus, blunt and 
hyaline 
pseudopodium, slow 
movements 
Cysts (size, 
nucleus) 
12 to 15 μm; mature cyst has four 
nuclei; immature cyst has one or two 
nuclei 
6 to 8 μm; mature cyst 
has four nuclei; immature 
cyst has one or two 
nuclei; two nucleated 
cysts very common 
15 to 25 μm; mature 
cyst has eight nuclei, 
rarely 16 or more 
nuclei 
10 to 15 μm; one nucleus, 
very rarely binucleated or 
quadrinucleated 
6 to 8 μm; one nuclei 
Appearance of 
trophozoites 
Stained trophozoites with fine, 
uniform granules of peripheral 
chromatin, and small central 
karyosome in nucleus; ingested RBC 
(E. dispar and E. moshkovskii are 
similar to E. histolytica trophozoites, 
sometimes ingested RBCs) 
Nuclear structure similar 
to E. histolytica; 
cytoplasm finely 
granular; ingested 
bacteria 
Nuclear with irregular 
cluster of peripheral 
chromatin; large, 
irregular, eccentric 
karyosome 
Nucleus with minute central 
karyosome, with fine 
granules of peripheral 
chromatin, finely granular 
cytoplasm; ingested bacteria 
Nucleus with large 
karyosome; no 
peripheral chromatin 
Appearance of 
cysts 
Typical nuclear structure is uniform 
size in having both karyosome and 
peripheral chromatin, chromatoidal 
bars with squared or rounded ends 
Typical nuclear structure, 
chromatoidal bars with 
rounded or squared ends 
Typical nuclear 
structure, sliver-shaped 
or irregular 
chromatoidals 
Mononucleated; large 
central karyosome; 
chromatoid bars with 
pointed or angular ends, 
inclusion masses 
Chromatin, four 
nuclei with large 
karyosomes and no 
peripheral chromatin 
Pathogenicity Only E. histolytica is pathogenic (E. 
dispar and E. moshkovskii are 
nonpathogenic) 
Nonpathogenic Nonpathogenic Nonpathogenic Nonpathogenic 
Adapted from (Tanyuksel and Petri, 2003) 
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Figure 1.3 Amoebas found in stool specimens of humans 
  Adapted from (Baron, 1996) 
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Among these Entamoeba species, only E. dispar and E. moshkovskii gained the 
attention from clinicians and researchers as both amoebas are morphologically 
indistinguishable from E. histolytica by microscopy. Both can only be differentiated 
at the molecular level as they are genetically distinct.  
E. dispar was first described by Brumpt in 1925 as a E. histolytica-like 
nonpathogenic strain (Jackson, 1998; Ackers, 2002). However, Diamond and Clark 
described it as a new species although it was closely related to E. histolytica (Diamond 
and Clark, 1993). Later, this nonpathogenic E. histolytica was renamed as E. dispar 
by Diamond and Clark in 1993 (Diamond and Clark, 1993; Stauffer and Ravdin, 2003; 
Tanyuksel and Petri, 2003). In 1997, E. dispar was officially classified as a 
nonpathogenic Entamoeba species by World Health Organization (WHO, 1997). 
Despite being claimed as a nonpathogenic Entamoeba species, some patients infected 
with E. dispar showed intestinal amoebiasis symptom (Jetter et al., 1997). It was able 
to produce variable focal intestinal lesions in animals and can rupture monolayer of 
epithelial cell in vitro (Chadee et al., 1985; Vohra et al., 1989; Espinosa Cantellano et 
al., 1997; Espinosa-Cantellano et al., 1998). Although McMillan et al. (1984) had 
reported E. dispar as a human pathogen, there was no further verification due to the 
absence of large case-controlled studies on the this species.  
A couple of pathogenicity studies of E. dispar were demonstrated using animal 
model, in which similar hepatic and intestinal lesions were observed to those caused 
by E. histolytica (Costa et al., 2000; Gomes et al., 2000). To make it worse, E. dispar 
strains isolated from asymptomatic patients were reported to have successfully induced 
ALA experimentally in hamsters (Dolabella et al., 2012; Guzman-Silva et al., 2013). 
However, Oliveira et al. (2015) suggested that more further studies should be 
conducted on the association between pathogenic enterobacteria with E. dispar in 
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favouring the expression of amoebic virulence factors responsible for the formation of 
epithelial lesions which favour the invasion and adhesion of E. dispar. This is because, 
pathogenic enterobacteria were found to be able to increase the virulence of E. 
histolytica and the same thing might happen to E. dispar (Galvan-Moroyoqui et al., 
2008). 
E. moshkovskii was first described by Tshalaia in 1941 from Moscow sewage. 
Since then the amoeba was reported in many other different countries (Scaglia et al., 
1983; Clark and Diamond, 1991). E. moshkovskii was initially thought to be a free-
living environmental strain until an E. histolytica-like strain was found and isolated 
from a resident who stayed in Laredo, Texas (Dreyer, 1961). It was named as E. 
histolytica Laredo strain due to its osmotolerant and resistant to emetine capacity that 
distinguished it from E. histolytica and E. dispar (Clark and Diamond, 1991; Clark 
and Diamond, 1997). Subsequently, this strain was confirmed and recognised as E. 
moshkovskii through molecular studies (Clark and Diamond, 1991). Some recent 
studies have reported the recovery of E. moshkovskii from human faeces based on 
microscopy, which makes the reports confusing as it cannot be distinguished from E. 
histolytica (Ali et al., 2003; Parija and Khairnar, 2005; Fotedar et al., 2007b; 
Tanyuksel et al., 2007). Although a study from India shows E. moshkovskii as a sole 
potential enteropathogen in patients, however further studies should be performed to 
investigate its pathogenic potential in human (Parija and Khairnar, 2005). 
 
1.4 Laboratory diagnosis of amoebiasis 
Traditionally, the diagnosis of amoebiasis is based on microscopic examination 
of biological samples. Detection of the pathogen then was shifted to molecular 
biology-based diagnostic tests as the technology advances. Various protein detection 
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assays were developed, which include enzyme-linked immunosorbent assay (ELISA), 
indirect haemagglutination assay (IHA) and latex agglutination. The introduction of 
DNA detection-based assays has helped to overcome the weakness of microscopy to 
enable the detection and differentiation of E. histolytica from other nonpathogenic 
Entamoeba species (Petri and Singh, 1999; Fotedar et al., 2007a). 
 
1.4.1 Microscopy 
Microscopic examination of stool samples is the most common routine 
diagnostic method used in many parasitology laboratories for diagnosis of both 
intestinal and extraintestinal amoebiasis. Stool examination should be done within 4 h 
before the trophozoites die of environmental stress (Tan et al., 2010). The routine 
microscopic stool observation method involves three common steps, which are wet 
preparation, concentration, and permanently stained smears. The cysts and 
trophozoites observation using direct wet mount is simple and easy to perform despite 
its low sensitivity of only up to 60% (Fotedar et al., 2007a). This method can be further 
verified with identification of trophozoites containing red blood cells for patients with 
dysentery. However, erythrophagocyted trophozoites will only be observed in stool 
samples of patients presented with acute dysentery (Huston et al., 1999). Besides, stool 
sample with E. dispar containing red blood cells were also reported (Haque et al., 
1995). Despite the well-established modified iron haematoxylin permanent stains and 
Wheatley trichrome staining techniques (Fotedar et al., 2007a), eosin Y staining 
method was reported to be more efficient and easier to perform (Tan et al., 2010). 
Eosin Y could rapidly stain the trophozoites with light red colour, while the central 
karyosome and chromatin materials were stained distinctly dark. Experienced and 
skillful personnel has always been important criteria for microscopic examination and 
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interpretation of results (Barrett-Connor, 1971; Mukhopadhyay et al., 2000). Presence 
of nonpathogenic Entamoeba species further increase the application doubt for 
identification of E. histolytica using microscopic examination (Haque et al., 1995; 
WHO, 1997; Tanyuksel and Petri, 2003; Haque and Petri, 2006; Liang et al., 2009). 
Therefore, a microscopic examination result should be verified by molecular assay 
(Fotedar et al., 2007a). 
 
1.4.2 Biochemical methods  
Biochemical method uses artificial enriched media such as TYI-S-33, Locke-
egg medium and TYSGM-9 to axenically culture the isolated trophozoites from patient, 
followed by isoenzyme analysis. Axenic culture of E. histolytica involves growing of 
the parasites in a medium without the presence of any microorganism except the 
intended protozoa. This method could distinguish the pathogenic E. histolytica from 
other nonpathogenic Entamoeba species (Sargeaunt et al., 1978; Fotedar et al., 2007a). 
Isoenzyme analysis differentiates Entamoeba spp. based on zymodeme.  Zymodeme 
is defined as a group of ameba strains that share the same electrophoretic pattern and 
mobilities for several enzymes namely phosphoglucomutase, hexokinase, malic 
enzyme and glucose-6-phosphate isomerase (Sargeaunt et al., 1987; Razmjou et al., 
2006).  Twenty-four different zymodemes have been described, of which 21 are from 
human isolates (12 of E. dispar and 9 of E. histolytica) and another three are from 
experimentally cultured amoeba strains.  
Although this method can differentiate E. histolytica from E. dispar, axenic 
culture of E. histolytica is not feasible in a clinical diagnostic laboratory due to its 
time-consuming process (Clark and Diamond, 2002). Moreover, culture technique is 
not only labour-intensive, it may not always be successful (Ackers, 2002; Clark and 
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Diamond, 2002; Haque and Petri, 2006). The selection bias on cultivated amoeba may 
generate false negative result due to outgrown of non-Entamoeba species during 
culture (Gonzalez-Ruiz et al., 1994; Haque et al., 1995). Furthermore, zymodeme 
analysis is low in analytical sensitivity or high in limit of detection as it requires large 
number of cells for the enzyme analysis. Therefore, isoenzyme analysis is no longer 
suitable for diagnosis of amoebiasis. 
 
1.4.3 Antibody detection 
Serological method is useful for diagnosis of amoebiasis in non-endemic 
countries where background amoebic antibodies are low. However, application of 
serological diagnosis is a challenge in amoebiasis endemic areas. This is because 
Entamoeba antibody detection is unable to differentiate recent infection from past 
infection in endemic areas (Caballero-Salcedo et al., 1994; Pillai et al., 1999). 
However, serological method was reported to be 100% sensitive based on screening 
of anti-amoebic antibodies in serum samples at China (Zengzhu et al., 1999). There 
are various antibody detection tests for amoebiasis such as counterimmuno-
electrophoresis, ELISA, indirect immunofluorescence assay, IHA, amoebic gel 
diffusion, indirect fluorescent assay, complement fixation and latex agglutination 
(Fotedar et al., 2007a). Among them, ELISA is the most commonly used format 
because it is highly sensitive for antibody detection and can be fully automated.  It was 
reported to be useful for diagnosis of extraintestinal infections when amoeba cannot 
be detected in faeces (Rosenblatt et al., 1995). In addition, it can be easily performed 
in a clinical laboratory (Fotedar et al., 2007a).  
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1.4.4 Antigen detection 
Antigen detection method could differentiate E. histolytica and E. dispar based 
on presence of lectin (Haque et al., 1997; Haque et al., 1998). TechLab E. histolytica 
II (TechLab, Blacksburg, VA) is a commercial antigen detection test for diagnosis of 
amoebiasis. This kit was reported to have high specificity of between 93 to 100% and 
sensitivity of up to 100% (Fotedar et al., 2007a). Besides its application on stool, this 
kit was reported to detect circulatory lectin antigen in serum, saliva and aspirated liver 
pus samples (Haque and Petri, 2006; Fotedar et al., 2007a). However, study conducted 
by Zeehaida et al. (2008) revealed that TechLab Entamoeba histolytica II kit only 
worked effectively on ALA patients who have yet to receive treatment prior to 
specimen collection. Another study demonstrated that this kit recorded a sensitivity of 
only up to 14.3% for E. histolytica detection compared to zymodeme and culture 
identification (Gatti et al., 2002). In addition, false positive results of this test were 
also being suspected (Furrows et al., 2004; Visser et al., 2006). Hence, the specificity 
and sensitivity of antigen detection using the TechLab kits should be re-evaluated 
(Gatti et al., 2002; Gonin and Trudel, 2003). 
 
1.4.5 DNA-based detection 
DNA-based detection method is usually accompanied by DNA amplification 
process such as PCR. This method is being endorsed by WHO for detection of E. 
histolytica and has been widely studied and utilised in developed and some developing 
countries (Zaki et al., 2002; Calderaro et al., 2006; Hamzah et al., 2006; Haque and 
Petri, 2006). It can detect E. histolytica in variety of clinical specimens, and even 
differentiate E. histolytica from other morphologically distinguishable nonpathogenic 
Entamoeba species (Tanyuksel and Petri, 2003; Fotedar et al., 2007a; Parija et al., 
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2014). Many genes have been described for detection of E. histolytica such as 30-kDa 
surface antigen gene, small-subunit ribosomal RNA genes, M17 genes, and some 
extrachromosomal circular DNA genes. Among those genes, small-subunit ribosomal 
RNA is the most widely used gene sequence due to its multi-copy and 
extrachromosomal features (Bhattacharya et al., 1989; Fotedar et al., 2007a). 
Initially, PCR approach was merely used to specifically identify the pathogenic 
E. histolytica. However, conventional single target PCR was found to be time-
consuming and labour-intensive since separate PCR runs are required to identify 
different species of Entamoeba. Since then, PCR-based detection method has been 
transformed into multiple advanced formats such as multiplex PCR, nested PCR and 
real-time PCR. Multiplex PCR is a platform that offered simultaneous detection of two 
or more targets in a single reaction by using more than a pair of primers. A single 
round PCR assay developed by Hamzah et al. (2006) was a good example where this 
assay was reported to be able to detect E. histolytica, E. dispar and E. moshkovskii 
simultaneously. Simultaneous multiple target amplification is benefiting as co-
infection between E. histolytica and E. dispar did occur. For example, a study in Cuba 
reported that with 24.5% of those screened had mixed E. histolytica and E. dispar 
infection (Nunez et al., 2001). Another study by Haque et al. (1998) found 18% of 
mixed infection cases in stool samples collected from symptomatic patients at Dhaka, 
Bangladesh.  
Real-time PCR is a highly sensitive but sophisticated machine-dependent 
amplification technique. Unlike conventional PCR, this technique does not require 
agarose gel electrophoresis to analyse its product. Instead, it uses sophisticated 
computerised machine to amplify and simultaneously quantify their targeted DNA 
molecule. Real-time PCR amplification was reported to be sensitive and specific for 
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diagnosis of amoebiasis. In addition, it offers direct sample analysis while 
amplification is still ongoing hence eliminated the need for post-PCR analysis and 
reduces the total assay time (Fotedar et al., 2007a). Various real-time PCR tests have 
been published for detection of E. histolytica (Roy et al., 2005; Haque et al., 2007) 
with some even possess the ability to differentiate among Entamoeba species (Lau et 
al., 2013; Gomes Tdos et al., 2014).  
Non-specific or cross-amplification has always been the concern for detection 
of E. histolytica in stool sample. This is because DNA from other organisms may be 
isolated from stool and get detected if the primers involved in amplification are not 
specific. Hence, nested PCR offered a better specificity platform by having two sets of 
primers to amplify a gene target in two successive runs. Khairnar and Parija (2007) 
have developed a novel nested multiplex PCR assay for differential detection of E. 
histolytica, E. moshkovskii and E. dispar in stool samples. This combination of 
multiplex PCR and nested PCR assay offers multiple targets detection with higher 
specificity in a single reaction. To further reduce the multiple pipetting steps during 
PCR preparation and to solve the time-consuming two successive runs of PCR, a 
ready-to-use single reaction cycle nested multiplex PCR assay was developed by Foo 
et al. (2012).  
Unlike other detection platform, DNA-based detection assays could be applied 
on stool samples with or without preservative (Tanyuksel and Petri, 2003; Fotedar et 
al., 2007a). PCR had also been reported for detection of E. histolytica in aspirated 
pus/abscess, urine and saliva (Ahmad et al., 2007; Parija and Khairnar, 2007; Othman 
et al., 2010). One of the disadvantages of using PCR method to detect E. histolytica in 
faecal samples is due to the presence of amplification inhibitors. The amplification 
inhibitors in form of molecules complexes such as bile salts, bilirubins, heme and even 
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carbohydrates could be co-extracted along with the pathogen DNA (Holland et al., 
2000). A new amplification approach which uses single temperature to amplify target 
gene has further simplified the process of DNA amplification process. This loop-
mediated isothermal amplification (LAMP) which only require a single temperature to 
complete the strand displacement, annealing and extension processes made it 
optionally eliminates the need of thermal cyclers (Notomi et al., 2000; Fotedar et al., 
2007a). This method uses DNA polymerase that perform displacement activities 
without denaturising the double-stranded DNA requires only 30 to 60 min to amplify 
a target gene (Notomi et al., 2000). Liang et al. (2009) has reported that a LAMP assay 
was as sensitive and specific as the conventional nested PCR for detection of E. 
histolytica in clinical stool specimens. Another LAMP assay for detection of E. 
histolytica was then developed by Rivera and Ong (2013) and the authors claimed that 
the assay could detect as low as five parasites per reaction. A LAMP assay applicability 
assessment was conducted by Singh et al. (2013) on specimens with clinical suspicion 
of ALA. The comparison assessment done with conventional PCR showed LAMP 
have better detection sensitivity. Hence, LAMP amplification platform is a potentially 
reliable tool for diagnosis of amoebiasis. 
 
1.5 Point-of-care diagnostic test 
The emergence of point-of-care or ready-to-use diagnostic platform offers 
spontaneous result analysis with minimal machine dependency. This diagnostic 
platform was deemed relevant for better disease control in the developing countries as 
it is Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free 
and Deliverable (ASSURED) (Wu and Zaman, 2012). The initial priorities for 
development of ‘ASSURED’ diagnostics focused on sexually transmitted diseases 
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such as syphilis, gonorrhoea and chlamydia (Kettler et al., 2004). The point-of-care 
diagnostic platform could also optionally avoid the need of huge and expensive 
equipment such as ELISA reader, gel electrophoresis system and thermal cycler. Thus, 
ASSURED complied tests are the preferred choice for diagnosis of infection disease 
in developing country with low resources setting.  
 A diagnostic assay made of a molecular amplification method combined with 
a lateral flow device is one of the current practicable diagnostic platform. This is 
because of the practicality of result analysis using lateral flow strips in low resource 
setting including highly portable, simple to use, cheap to produce and produce rapid 
visual result characteristics. Reported point-of-care diagnostic assays such as dry-
reagent lateral flow for the detection of Vibrio cholerae with PCR (Chua et al., 2011a) 
and LATE-PCR with dry-reagent nucleic acids-based lateral flow assay (Ang et al., 
2015) have shown good potential as they were highly sensitive and specific. However, 
the PCR amplification incorporated in these assays made them dependent on thermal 
cycler. Various studies were conducted to obviate the use of thermal cycler. A 
combination of LAMP amplification with lateral flow technology was reported to have 
work as efficiently as PCR-lateral flow assays (Surasilp et al., 2011). Since then, many 
assays were reported for various targets based on this LAMP-lateral flow combination 
(Rigano et al., 2014; Yongkiettrakul et al., 2014; Thongkao et al., 2015; Najian et al., 
2016). Incorporation of LAMP amplification in replacing PCR not only eliminated the 
needs of sophisticated machine (thermal cycler), it also cuts short the amplification 
duration as LAMP amplification performance is much higher than PCR (Notomi et al., 
2000). 
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1.5.1 Loop-mediated isothermal amplification 
Generally, DNA-based isothermal amplification or single temperature 
amplification is divided into four different categories, namely LAMP, strand 
displacement amplification (SDA), helicase-dependent amplification (HDA) and 
nicking enzyme amplification reaction (NEAR). The differences among these 
isothermal platforms were involvement of different enzymes that assisted strand-
displacement and primers design. Among those, LAMP is the most frequently reported 
isothermal amplification platform for detection of pathogens (Yan et al., 2014). LAMP 
uses high strand displacement activity DNA polymerase, an in silico designed 
homologue of Bacillus stearothermophilus to catalyse the auto-cycling stand-
displacement activity under a single temperature ranging 55 to 65°C (Notomi et al., 
2000). This amplification provides high target specificity because it uses four to six 
primers that recognise six to eight distinct regions of target DNA (Notomi et al., 2000; 
Nagamine et al., 2002). There are three different primer pairs involved in LAMP, 
which are inner primers (form with F1c-F2 or B1c-B2 target regions), outer primers 
(form with F3 or B3 target region) and loop primers as illustrated in Figure 1.4.  
The amplification process starts when the F2 region of the inner primer 
hybridises to the target and the DNA sequence extended by Bst DNA polymerase. 
Displacement process takes place when the outer primer binds to F3 complementary 
(F3c) region of the same target and extended the F3 DNA sequence to further displace 
the newly synthesised strand. The first displaced strand will then form a stem-loop 
structure at the 5’ end due to the hybridisation of F1c and F1 region. A new strand 
with stem-loop structure at both ends is generated when the backward inner primer 
and outer primer repeated the displace-amplification process at the 3’ end of the 
previous strand. This process produces a dumbbell-like structured DNA which later  
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Figure 1.4 Primers for loop-mediated isothermal amplification 
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involved in series of amplification cycle that beyond exponential (Notomi et al., 2000). 
To further improve the amplification performance, a pair of loop primers were 
suggested to be incorporated. This set of primer will join into the amplification process 
by binding at the stem-loop of the dumbbell-like structure extended their sequence to 
form a brand new double-stranded structure. Inclusion of loop primers not only 
improve the amplification, additional primers that recognises specific sequence would 
improve its specificity of the amplification (Nagamine et al., 2002). Even when large 
amounts of non-target DNA are present, LAMP was still able to amplify up to 109 
copies of the target within one hour (Notomi et al., 2000). Thus, LAMP has been 
widely applied to rapidly detect pathogens, including E. histolytica (Liang et al., 2009; 
Rivera and Ong, 2013; Singh et al., 2013). Although these assays were reported to be 
as sensitive as PCR platform for detection of E. histolytica, they are still dependent on 
sophisticated equipment such as electrophoresis system, turbidimeter and UV light-
related analyser. 
 
1.5.2 Lateral Flow 
The lateral flow-based nucleic acid detection platform can be classified into 
competitive and non-competitive approaches. Non-competitive platform can be further 
classified based on the type of immobilised capture reagent on the lateral flow strip. A 
lateral flow system with immobilised hapten or antibody on the reaction pad is named 
nucleic acid lateral flow immunoassay (NALFIA) whereas lateral flow system with 
immobilised oligonucleotides on the reaction pad is referred as nucleic acid lateral 
flow (NALF) assay. NALFIA can be further diverged into hybridisation and non-
hybridisation categories. NALFIA that detect double-labelled amplicon with probe 
hybrids is classified as hybridisation-based while assays that detects double-labelled 
